American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Perspective Therapeutics, Inc. (CATX)

$1.61 -28.76% NYSE: CATX · 15-min delayed

SEATTLE, Washington
Public · NYSE: CATX
166 employees

Visit website Follow

$331.9MMarket cap

$5.9MRevenue · FY2018

-$103.1MNet income

166Employees

CATXNYSE

2003IPO

About Perspective Therapeutics, Inc.

Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NYSE: CATX
Employees: 166
IPO date: Dec 29, 2003
Headquarters: 2401 ELLIOTT AVENUE
SEATTLE, Washington 98121
Phone: 206-676-0900
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: CATX NYSE
SEC CIK: 728387
LEI: 549300I1AHR8KMMFIS52
EIN: 411458152
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Perspective Therapeutics, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/perspective-therapeutics-inc/"><img src="https://americancompanies.com/badge/perspective-therapeutics-inc.svg" alt="Perspective Therapeutics, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Perspective Therapeutics, Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2018: $5.9M
Net income: -$103.1M
Total assets: $267.0M
Market cap: $331.9M

Source: SEC EDGAR · updated Jun 7, 2026

NYSE: CATX

$1.61 -28.76%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$1.61 $5.65

52-week range

Market cap: $331.9M
Shares outstanding: 206.1M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Dec 29, 2003

Perspective Therapeutics, Inc. (CATX) Stock Price

Reported a net loss of $103.1M in FY2018.
Trading 72% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Perspective Therapeutics, Inc..

Write a review

Newsroom

News about Perspective Therapeutics, Inc.

Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength? Zacks Investment Research · 2026-10-09 · neutral Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma GlobeNewswire Inc. · 2026-05-21 · positive Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsight GlobeNewswire Inc. · 2026-04-20 · positive Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting GlobeNewswire Inc. · 2026-04-20 · positive Perspective Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire Inc. · 2026-04-02 · positive New Treatment Modalities Are Reaching Cancers That Resisted Everything Else Benzinga · 2026-02-17 · positive

News & sentiment via Polygon.io

FAQ

Perspective Therapeutics, Inc.: frequently asked questions

Is Perspective Therapeutics, Inc. an American company?

Perspective Therapeutics, Inc. is a US-based company headquartered in Seattle, Washington, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Perspective Therapeutics, Inc. headquartered?

Perspective Therapeutics, Inc. is headquartered in Seattle, Washington, United States.

Is Perspective Therapeutics, Inc. publicly traded?

Yes — Perspective Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol CATX on the NYSE.

What does Perspective Therapeutics, Inc. do?

Perspective Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore